Diabetic patients on Toujeo showed lower rate of severe hypoglycemia in analysis
Sanofi said it has found adults with type 2 diabetes treated with its Toujeo® insulin injection experienced a consistently lower rate of confirmed or severe hypoglycemia both at night and at any time of the day when compared with Lantus®.
Results of the meta-analysis from the EDITION 1, 2 and 3 Phase 3 clinical trials in patients with type 2 diabetes were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes in Germany. It shows promise for those type 2 diabetes to achieve equivalent glycemic control with less hypoglycemia.
“For people with diabetes, it is vital to achieve good glycemic control in order to minimize the risk of microvascular complications,” said Pratik Choudhary, Senior Lecturer and Consultant in Diabetes, King's College London, UK and lead author of the presentation.
The results showed patients treated with Toujeo experienced a mean estimated reduction in HbA1c of 0.64% (p<0.0001) after 6 months of treatment, while the occurrence of hypoglycemia was 6.0% at baseline and 5.1% at follow-up, the researchers said.
Sanofi is conducting three large, randomized clinical trials — ACHIEVE, REACH and REGAIN CONTROL — evaluating in real-life conditions the effect of Toujeo in people with type 2 diabetes.